The effects of the fenretinide and genistein as single or combined drugs on ovarian cancer proliferation and viability were investigated.
Hypothesis: Co-treatment with genistein will enable a lower dose of fenretinide to be effective in inhibiting the proliferation and survival of ovarian cancer cells.
Methods: Low and high doses of genistein and fenretinide were tested on A2780s and A2780cp cells using trypan blue viable cell count, MTS assay.
Results and conclusions: Unlike low doses of fenretinide, genistein had anti-proliferative effects on both cell lines. There were no additive or synergistic effects of the two compounds. Higher dose treatments induced anti-proliferative effects and apoptotic cell death in both A2780s and A2780cp cells, with a greater sensitivity of A2780s cells to both test compounds.
Overall Conclusion: Genistein and higher doses of fenretinide similarly impair cell cycle progression and induce apoptosis. The anti-proliferative effects of genistein can be affected by co-treatment with fenretinide
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:OOU.#10393/20530 |
| Date | 10 January 2012 |
| Creators | Azadi, Behnam |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | English |
| Detected Language | English |
| Type | Thèse / Thesis |
Page generated in 0.0024 seconds